Camlin Fine Sciences Limited · NSE:CAMLINFINE
Camlin Fine Sciences — Q2 FY26 Earnings Presentation
23 slides from Camlin Fine Sciences's earnings presentation, November 2025
Slide 1: Investor Presentation – November 2025
INTEGRATING SOLUTIONS ADDING VALUE Investor Presentation – November 2025 Camlin Fine Sciences Limited
Slide 2: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Camlin Fine Sciences Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 3: Q2 & H1FY26 Performance Highlights
Q2 & H1FY26 Performance Highlights
Slide 4: Q2 & H1FY26 Operational Highlights
FY25 Q2 Operational & H1FY26 Highlights Operational Highlights Revenue (Rs. In Mn) EBITDA (Rs. In Mn) 8,899 907 8,188 515 524 4,230 4,286 4,614 7,982 8,834 334 4,598 190 4,173 4,236 57 50 15 207 66 Q2 FY25 Q1 FY26 Q2 FY26 H1 FY25 H1 FY26 Q2 FY25 Q1 FY26 Q2 FY26 H1 FY25 H1 FY26 EBITDA Margin % PAT (R
Slide 5: Q2 & H1FY26 Highlights
FY25 Q2 Operational & H1FY26 Highlights Highlights From Continuing Operations • Revenue in the quarter improves to Rs. 4,598 mn, a growth of 8.6% • Revenue for Speciality Ingredients Straights grew, however demand remains sluggish with local competition on the horizon • Blends business witnessed ste
Slide 6: Operational Revenue Breakup
Operational Revenue Operational RevenueBreakup Breakup From Continuing Operations Specialty Ingredients (Rs. In Mn) Specialty Ingredients (Rs. In Mn) Total Specialty Ingredients (Rs. In Mn) (Straights) (Value added blends) -14% +7% +1% 1,955 4,721 6,364 6,404 4,409 1,683 +3% +4% +9% 977 2,256 2,327
Slide 7: Regional Highlights
Regional Highlights Regional Highlights From Continuing Operations CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) 4,355 2,523 2,451 312 4,088 283 2,440 183 2,269 1,206 1,250 1,201 1,914 132 129 Q2 FY25 Q1 FY26 Q2 FY26 H1 FY25 H1 FY26 Q2 FY25 Q1 FY26 Q2 FY26 H1 FY25 H1 FY26 Q2 FY
Slide 8: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement From Continuing Operations Particulars (Rs. In Mn) Q2 FY26 Q2 FY25 Q1 FY26 H1FY26 H1FY25 Revenue from Operation 4,598.3 4,173.2 4,235.5 8,833.8 7,981.7 Raw material consumption 2,467.2 2,157.7 2,368.8 4,836.0 4,198.9 Employee Cost 602.9 479.9 595.7 1,198.6 942.5
Slide 9: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (Rs. In Mn) Sept – 25 Mar – 25 Particulars (Rs. In Mn) Sept – 25 Mar – 25 Equity Non-Current assets Equity Share Capital 188.0 187.9 Property, Plant and Equipment 5,849.1 5,925.6 Capital Work-In-Progress 146.5 97.3 Other Equity 8,707.7 8,828.8 Right use of asse
Slide 10: Company Overview
Company Overview
Slide 11: Company Overview
Company Overview FY25 Revenue Mix*# ₹ 16,319 mn 100+ 1,250+ Range of Diversified Base of Satisfied 23% Products offerings Customers Worldwide Preferred Partner High Quality & Wide For Customized Shelf-Life Solutions Range Vanillin Manufacturer 54% Among Global 49,000+ Specialty Ingredients Leaders L
Slide 12: Global Footprint
Global Footprint 7 Global Manufacturing Facilities 6 Application Laboratories 80+ Presence in Countries 2 R&D Centres Map not to scale. All data, information and maps are provided “as is” without warranty or any representation of accuracy, timeliness or completeness. 12
Slide 13: Product Highlights
Product Highlights FY25 Sales%*# Key Products End User Industries Key Brands › TBHQ › Pet Food › Animal Feed Mills Straights 23% › BHA › Livestock Nutrition › Biodiesel › Ascorbyl palmitate (ASP) › Food & Beverages › Aquaculture & Fishmeal › Fish Meal › Rendering Specialty Ingredients › 200+ custom
Slide 14: Innovation at Work
Innovation at Innovation at Work Work Process Optimization Initiatives • Vanillin Production Optimization: Continuous improvement at Dahej plant, refining processes and setting a future – oriented strategic direction • Animal Nutrition: Dedicated to the continuous improvement and development of prod
Slide 15: Manufactured In-house Integration Chain
Integration Chain Phenol Hydroquinone Diphenols Catechol Manufactured In-house Performance Performance Specialty Ingredients Chemicals Aroma Ingredients Chemicals Ascorbyl Palmitate1 TBHQ MEHQ Guaiacol Guethol BHA Other derivatives of HQ Veratrole Vanillin Other derivatives of Blends Ethyl Vanillin
Slide 16: ESG
ESG ESG • Main goal by 2030 is to switch to renewable electricity for all manufacturing facilities. Currently, company is exploring different options to achieve this goal • Dedicated to sustainability and done few initiatives from reducing food waste to sourcing clean energy Environment • Constantly
Slide 17: Board Of Directors
Board Of Directors › Over three decades of experience in pharmaceuticals and › Managing Director of the MJ Group with over three decades of specialty chemical products including business planning, Ashish Dandekar Amol Shah experience covering human healthcare, F&F compounds, plant information system
Slide 18: Senior Management Team
Senior Management Team Ashish Dandekar › Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information systems, research & Chairman & Managing Director development, product development, and marketing › Holds a BA in Economics and Managem
Slide 19: Historical Financial Highlights
Historical Financial Highlights
Slide 20: Historical Financial Highlights
Historical Financial Highlights Revenue (Rs. In Mn) EBITDA (Rs. In Mn) PAT (Rs. In Mn) 15.3% 10.8% 12.7% 7.0% 9.3% Margin 16,816 16,131 16,928 654 604 2,131 1,574 398 14,121 1,819 978 530 494 11,871 1,528 14,539 16,665 1,836 2,081 -1,578 -2,075 1,591 -507 -1,049 263 -858 -1,581 FY21 FY22 FY23 FY24 F
Slide 21: Operational Revenue Break-Up
Operational Revenue Break-Up Specialty Ingredients (Rs. In Mn) Specialty Ingredients (Rs. In Mn) Total Specialty Ingredients (Rs. In Mn) (Straights) (Value added blends) 12,605 11,585 4,576 8,784 9,679 4,111 7,474 3,812 3,821 7,980 2,860 5,103 6,171 4,168 3,311 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY2
Slide 22: Regional Highlights
Regional Highlights CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) 8,865 4,822 5,062 4,883 7,894 7,733 4,395 6,855 3,762 6,000 3,533 3,198 2,735 679 525 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 CFS Brazil (Rs. In Mn) CFS North America (Rs. In Mn
Slide 23: Thank You !
Thank You ! Camlin Fine Sciences Ltd. CIN – L74100MH1993PLCO75361 Santosh Parab- CFO Email – [email protected] [email protected] www.camlinfs.com www.camlinfs.com http://www.sgapl.net/images/sgapl_logo.jpg Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Shrikant San